Synageva sinks despite positive rare disease data
This article was originally published in Scrip
Executive Summary
Synageva BioPharma's Phase III ARISE trial of sebelipase alfa met the primary endpoint of normalization of alanine aminotransferase (ALT), a marker of liver injury, in patients with lysosomal acid lipase (LAL) deficiency. Despite the positive news, the company saw its share price close 14% down at $90.45 (1 July).